Oligodendroglioma is a malignant brain cancer that develops from specialized nervous cells called oligodendrocytes. Oligodendroglioma is one of the more common types of glioma (which also includes glioblastoma multiforme and astrocytoma) that can affect people of all ages. Rarely, families with multiple affected members have been reported, suggesting that a predisposition for oligodendroglioma can be inherited from blood relatives. Because oligodendroglioma is so rare, it has not been well-studied, due in part to a lack of available biospecimens and data for research use. The goal of this project is to generate whole genome sequencing with paired RNA sequencing for a cohort of Oligodendroglioma across pediatric, adolescent and adult patients to map the key characteristics of these tumors. Whole genome sequencing (WGS) data identifies all of the genes in a genome and RNA sequencing analyzes the RNA found in a sample or gene expression. Both of these data types are integral to the continued study of this disease, and this project will create the largest open access cohort of oligodendroglioma data. The Children's Brain Tumor Network contributed to this project by providing DNA and RNA samples for sequencing, samples that are unavailable elsewhere.
What are the goals of this project?
Researchers will perform WGS and RNA sequencing on rare oligodendroglioma specimens in an effort to better understand this rare disease.
What is the impact of this project?
The dataset created through this project will send the groundwork for continued research into therapies for oligodendroglioma.
Why is the CBTN request important to this project?
Pediatric oligodendroglioma specimens are rare, making the Children’s Brain Tumor Network provision of such DNA and RNA samples integral to this project.
The Children's Brain Tumor Network contributed to this project by providing DNA and RNA samples for sequencing.
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a
Children’s Hospital of Philadelphia
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
Oligodendroglioma is a primary central nervous system (CNS) tumor. This means it begins in the brain or spinal cord.Oligodendrogliomas are grouped in two grades based on their characteristics.Grade II oligodendrogliomas are low grade tumors. This means the tumor cells grow slowly and invade nearby n